Diamedica, Inc. (DMCAF: OTCQB) | DiaMedica Inc. Announces Results of Annual General and Special Meeting of Shareholders


MINNEAPOLIS, MINNESOTA–(Marketwired – Oct. 23, 2015) – DiaMedica Inc. (TSX VENTURE:DMA)(OTCQB:DMCAF) (the “Company”), a clinical stage biopharmaceutical company focused on developing innovative treatments for stroke and other vascular diseases where no current therapies are available, today announced that at its Annual General and Special Meeting (the “Meeting”) of shareholders held on October 23, 2015, Michael Giuffre, James Parsons, Rick Pauls, Richard Pilnik, and Dawson Reimer were elected as the Company’s board of directors.

Mr. James Parsons previously served as Vice President of Finance for the Company from October 2010 until May 2014. Mr. Parsons is currently the Chief Financial Officer and Corporate Secretary of Trillium Therapeutics Inc., a NASDAQ-listed immune-oncology company. He has been a Chief Financial Officer in the life sciences industry since 2000 with experience in therapeutics, diagnostics and devices.

“We are very pleased to welcome Mr. Parsons to our board of directors. He is a highly respected member of the life sciences community and we are confident that his extensive business expertise will be instrumental as the Company executes its strategic plan,” said Rick Pauls, President and Chief Executive Officer of the Company.

Mr. Tom Wellner will be stepping down at the end of his term to focus his attention on his other commitments. “On behalf of our board of directors, we would like to thank Mr. Wellner for his numerous contributions,” Mr. Pauls said. “His leadership to DiaMedica these past seven-and-a-half years have been extremely valuable.”

In addition to the election of directors, the shareholders passed all resolutions placed before the Meeting as outlined in the management information circular dated September 18, 2015.

About DiaMedica

DiaMedica is a publicly traded clinical stage biopharmaceutical company focused on developing novel treatments for stroke and other vascular diseases. DiaMedica’s common shares are listed on the TSX Venture Exchange under the trading symbol “DMA” and on the OTCQB under the trading symbol “DMCAF”.


The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica’s expectations should be considered forward-looking statements. Such statements are based on management’s exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words “may”, “will”, “anticipate”, “believe”, “estimate”, “expect”, “intend” and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in DiaMedica’s filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. DiaMedica undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events, unless required by law. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.

Leave a Reply